Table 1.

Efficacy of ramucirumab in previously treated patients with gastric–GEJ adenocarcinoma

JVBDJVBE
Ramucirumab (n = 238)Placebo (n = 117)Ramucirumab/PAC (n = 330)Placebo/PAC (n = 335)
OS
 Number of deaths179 (75%)99 (85%)256 (78%)260 (78%)
 HRa (95% CI), Pb0.78 (0.60–0.998), P = 0.0470.81 (0.68–0.96), P = 0.017
 Median survivalc, mo (95% CI)5.2 (4.4–5.7)3.8 (2.8–4.7)9.6 (8.5–10.8)7.4 (6.3–8.4)
PFS
 HRa (95% CI), Pb0.48 (0.38–0.62), P < 0.0010.64 (0.54; 0.75), P < 0.001
 Median PFSc, mo (95% CI)2.1 (1.5–2.7)1.3 (1.3–1.4)4.4 (4.2–5.3)2.9 (2.8–3.0)

Abbreviation: PAC, paclitaxel.

  • aHR estimated using the Cox model.

  • bStratified log-rank test.

  • cKaplan–Meier estimate.